As whole-exome sequencing (WES) and whole-genome sequencing (WGS) move into routine clinical practice, it is timely to review data that might inform the debate regarding secondary findings (SF) and the development of policies that maximize participant benefit. Read the full article here:

http://www.nature.com/gim/journal/vaop/ncurrent/full/gim2016109a.html